VivoSeq
Oncology

Ocular Melanoma

22

Pipeline Programs↗

4

Active Trials↗

14

Companies Involved↗

Ocular Melanoma is an emerging landscape with 22 programs across 14 companies. The most active players are Bayer, Bristol-Myers Squibb, San Diego Pacific Oncology & Hematology Associates. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

6/100

Mech. Concentration

11/100

Completion Rate

67/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2S

San Diego Pacific Oncology & Hematology Associates

1 program

Phase 2I

IDEAYA Biosciences

1 program

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

78%

Small molecule

18 of 23 classified programs — the dominant modality here.

22%ALL OTHERSMonoclonal antibody29%Protein / enzyme29%Cell therapy14%

Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 23 pipeline programs.

Analysis

Trial Status

13

clinical trials

Completed4 · 31%
Unknown status3 · 23%
Active, not recruiting2 · 15%
Terminated2 · 15%
Recruiting1 · 8%
Enrolling by invitation1 · 8%

Clinical Trials

Trial Activity

13 trials

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
Recruiting·MMassachusetts General Hospital·N/A·NCT07364474·10 enrolled
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Active, not recruiting·IIDEAYA Biosciences·Phase 2·NCT05907954·160 enrolled
Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma
Active, not recruiting·SSt Vincent's Hospital, Sydney·Phase 2·NCT05187884·15 enrolled
Melphalan Chemoreduction for Ocular Melanoma
Enrolling by invitation·HHospital das Clínicas de Ribeirão Preto·Phase 1/2·NCT05893654·10 enrolled
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT00109005·17 enrolled
Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma
Completed·—·Phase 1·NCT01893099·11 enrolled
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
Completed·—·Phase 2·NCT01200238·17 enrolled
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
Completed·CCraig L Slingluff, Jr·Phase 1/2·NCT04364230·22 enrolled
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
Terminated·National Cancer Institute (NCI)·Phase 2·NCT01814046·24 enrolled
Imatinib in Adult Patients With Metastatic Ocular Melanoma
Terminated·CCentre Oscar Lambret·Phase 2·NCT00421317·13 enrolled
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
Unknown status·—·Phase 2·NCT03528408·52 enrolled
Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
Unknown status·SSan Diego Pacific Oncology & Hematology Associates·Phase 2·NCT00489944·50 enrolled
Study of Metastatic Ocular Melanoma
Unknown status·—·Phase 2·NCT00168870·48 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)